单核细胞趋化蛋白１（ ＭＣＰ１） 是近年来发展的新型抗肿瘤途径，具有募集单核细胞等不同的生物学机制，可克服骨肉瘤多药耐药性等问题，具有明显的优越性，有望成为一种新的骨肉瘤生物学途径。本文综述了ＭＣＰ１ 的来源、生物学特点、抗瘤作用机制，并探讨其应用于骨肉瘤治疗的可能性、优越性、存在的问题及其解决途径 Monocyte chemoattractant protein-1 (MCP-1) is a new anti-tumor pathway developed in recent years. It has different biological mechanisms such as the recruitment of mononuclear cells, which can overcome the problems of multidrug resistance of osteosarcoma and has obvious The superiority is expected to become a new biological approach to osteosarcoma. This article reviews the source, biological characteristics and anti-tumor mechanism of MCP-1, and discusses its possibility, superiority, existing problems and its solution to the treatment of osteosarcoma.